Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients.

Onco Targets Ther · 2015 · PMC4648607 · PMID 26648737

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

A strong trend toward a shorter OS was observed in patients receiving cetuximab as second-line therapy after bevacizumab.

also in 5,725 other papers

a favorable trendno p-value reported

In the no prior bevacizumab use group, the analysis showed a favorable trend but no significant difference in OS.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.